Genetic brain disorder fixed in mice using precision epigenome editing

The researchers found that this gene, C11orf46, is an important regulator during brain development. Specifically, it turns on and off the direction-sensing proteins that help guide the long fibers growing out of newly formed neurons responsible for sending electrical messages, helping them form into a bundle, which connects the two hemispheres of the brain. Failure to properly form this bundled structure, known as the corpus callosum, can lead to conditions such as intellectual disability, autism or other brain developmental disorders.

"Although this work is early, these findings suggest that we may be able to develop future epigenome editing therapies that could help reshape the neural connections in the brain, and perhaps prevent developmental disorders of the brain from occurring," says Atsushi Kamiya, M.D., Ph.D., associate professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine.

The study was published online in the September 11 issue of Nature Communications.

WAGR syndrome is also known as chromosome 11p13 deletion syndrome, which can result when some or all of the gene located in the region of chromosome 11p13 that includes C11orf46 is deleted by chance. The researchers used a genetic tool, short hairpin RNA, to cause less of the C11orf46 protein to be made in the brains of mice. The fibers of the neurons in the mouse brains with less of the C11orf46 protein failed to form the neuron bundled corpus callosum, as is found in WAGR syndrome.

The gene that makes Semaphorin 6a, a direction-sensing protein, was turned on higher in mice with lower C11orf46. By using a modified CRISPR genome editing system, the researchers were able to edit a portion of the regulatory region of the gene for Semaphorin. This editing of the epigenome allowed C11orf46 to bind and turn down the gene in the brains of these mice, which then restored the neuron fiber bundling to that found in normal brains.

Other authors on the study include Atsushi Saito, Yuto Hasegawa, Yuya Tanaka, Mohika Nagpal, Gabriel Perez and Emily Alway of Johns Hopkins; Cyril Peter, Sergio Espeso-Gil, Tariq Fayyad, Chana Ratner, Aslihan Dincer, Achla Gupta, Lakshmi Devi and Schahram Akbarian of Mount Sinai; John Pappas of New York University; François Lalonde of the National Institute of Mental Health (NIMH), John Butman of the National Institutes of Health (NIH) Clinical Center; and Joan Han of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

This work was supported by grants from the National Institute on Drug Abuse (DA041208), NIMH (MH091230, MH094268, MH104341, MH117790), the National Center for Complementary and Integrative Health (AT008547), a Johns Hopkins Catalyst Award, the Brain & Behavior Research Foundation, NICHD (ZIAHD008898), an NIH Bench-to-Bedside Award and Office of the Director at NIH (S10OD016374).

Han received grant funding from Rhythm Pharmaceuticals.